EcoDrugPlus

Notch Receptor 1a

Ensembl ID : ENSATEG00000013629
Gene Symbol: NOTCH1A
2 Cross references
195 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSATEG00000021480
Gene Symbol: NOTCH3
3 Cross references
193 Possible Orthologues:

Nuclear Factor, Erythroid 2-Like 2a

Ensembl ID : ENSATEG00000015291
Gene Symbol: NFE2L2A
3 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSATEG00000029349
Gene Symbol: NR1H3
3 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSATEG00000021539
Gene Symbol: NR1H4
3 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSATEG00000010600
Gene Symbol: NR3C1
4 Cross references
206 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSATEG00000005344
Gene Symbol: NR3C1
3 Cross references
207 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSATEG00000012390
Gene Symbol: NR3C2
3 Cross references
209 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSATEG00000003122
Gene Symbol: NOD2
3 Cross references
167 Possible Orthologues:

Opioid Receptor, Delta 1a

Ensembl ID : ENSATEG00000009358
Gene Symbol: OPRD1A
2 Cross references
195 Possible Orthologues:

Opioid Receptor, Delta 1b

Ensembl ID : ENSATEG00000023714
Gene Symbol: OPRD1B
3 Cross references
178 Possible Orthologues:

Opioid Receptor, Kappa 1

Ensembl ID : ENSATEG00000001556
Gene Symbol: OPRK1
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).